Topotarget plummets on another belinostat miss

Topotarget A/S (CSE:TOPO) plummeted DKK2.18 (60%) to DKK1.46 on Friday after reporting top-line data from the Phase II PXD101-CLN-17 trial to treat cancer of unknown primary (CUP) showing that belinostat plus carboplatin and paclitaxel missed the primary endpoint of progression-free survival vs. carboplatin and paclitaxel alone (5.4 vs. 5.3 months, p=0.5526). Belinostat plus chemotherapy did meet the secondary endpoint of improving objective response rate vs. chemotherapy alone (43.2% vs. 22.2%, p=0.0252), but non-significantly improved overall survival (p=0.2906). The open-label, international Phase II trial enrolled 89 patients with previously untreated CUP. Topotarget said it is still analyzing the data and has not yet determined next steps. ...